

## NCCN Breast Cancer Guidelines V.3.2010 – Update Webinar October 5, 2010

Guideline Page and Request	Panel Discussion	References	Vote*		
			YES	NO	ABSTAIN
<p>BINV-M Internal request: Institutional review; Review the use of bevacizumab with chemotherapy in metastatic breast cancer.</p> <p>External request: Submission from Genentech Inc.; Review the data for use of bevacizumab in patients with metastatic breast cancer.</p>	<p>The Panel discussed the FDA’s Oncologic Drugs Advisory Committee (ODAC) vote regarding the use of bevacizumab in combination with other chemotherapies for the first-line treatment of patients with HER-2–negative metastatic breast cancer.</p> <p>The Panel agreed to retain its recommendation for the use of bevacizumab in combination with paclitaxel for metastatic breast cancer and revise the related footnote, it now states: “Randomized clinical trials in metastatic breast cancer document that the addition of bevacizumab to some first or second line chemotherapy agents modestly improves time to progression and response rates but does not improve overall survival. The time to progression impact may vary among cytotoxic agents and appears greatest with bevacizumab in combination with weekly paclitaxel.”</p>	<p>1. O’Shaughnessy J, Miles D, Gray RJ, et al. A meta-analysis of overall survival data from three randomized trials of bevacizumab and first-line chemotherapy as treatment for patients with metastatic breast cancer. Presented at the 46th Annual Meeting of the American Society of Clinical Oncology in Chicago, IL; June 4-8, 2010. ASCO Oral Presentation #1005.</p> <p>2. Brufsky A, Rivera RR, Hurvitz SA, et al. Progression-free survival in patient subgroups in RIBBON-2, a Phase III trial of chemotherapy plus or minus bevacizumab for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer. Presented at the 46th Annual Meeting of the American Society of Clinical Oncology in Chicago, IL; June 4-8, 2010. ASCO Poster #1021.</p> <p>3. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. E-pub Date: 2010. DOI # 10.1200/JCO.2008.21.6457.</p>	15	0	0

\*Three Panel members had to leave the meeting prior to the vote being taken.